We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) to Provide Genomics Innovation Via New Tie-Ups
Read MoreHide Full Article
Agilent Technologies (A - Free Report) recently collaborated with Amazon’s (AMZN - Free Report) cloud computing platform Amazon Web Services (AWS) and NVIDIA (NVDA - Free Report) .
Per the terms of the deal, Agilent will leverage Amazon Elastic Compute Cloud G5g instances, NVIDIA T4G Tensor Core GPUs and NVIDIA Clara Parabricks’ advanced genomics analysis capabilities for improving processing speeds for variant calling workflows on its cloud-native Alissa Reporter software.
With the integration of NVIDIA Clara Parabricks platform into the Alissa secondary analysis pipelines, clinical labs and researchers can avail quick panel-specific data analysis solutions in a secure manner.
On the back of this partnership, Agilent aims to provide streamlined workflow solutions for its SureSelect family of next-generation sequencing (NGS) assays, which include a wide range of custom and catalog panels.
Notably, SureSelect panels are widely used to enrich samples for specific genes of interest as they ensure a cost-effective targeted sequencing process. With Amazon AWS’ cloud-based analysis expertise and NVIDIA’s compute capabilities, Agilent will advance this process and provide advanced analytical solutions in the genomics space.
The recent tie-up with Amazon’s AWS and NVIDIA is anticipated to help Agilent expand its presence in the booming genomics market.
The underlined market is witnessing significant growth owing to rising demand for genome sequencing for the diagnosis of critical diseases like cancer. Growing adoption of new products and software for storage, sequencing and analysis of large DNA information is further driving this market.
Per a Fortune Business Insights report, the market is expected to reach $94.7 billion in 2028, witnessing a CAGR of 19.4% between 2021 and 2028.
Also, a Grand View Research report states that the market is likely to see a CAGR of 15.4% during the same period.
A Slew of Partnerships
Agilent is consistently building partnerships to provide advanced technological solutions to serve its customers better.
Apart from the recent alliance, Agilent collaborated with APC Ltd., a provider of innovative small molecule and large molecule process design and process development solutions. Per the terms of the agreement, A aims to help customers in the biopharmaceutical and pharmaceutical industry develop higher quality drugs faster.
Moreover, Agilent is working with the Advanced Mammalian Biomanufacturing Innovation Center to advance technologies and bring innovative measurement tools for bioprocess development, and biomolecular, cell and gene-based therapeutics manufacturing applications.
Agilent also joined forces with Virtual Control whereby it integrated the latter’s advanced artificial intelligence technology into its industry-leading gas chromatography and mass spectrometry platforms to enhance lab productivity.
Zacks Rank & Another Stock to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy). Investors interested in the broader technology sector can also consider another top-ranked stock like Avnet (AVT - Free Report) , flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Avnet has gained 19% in the year-to-date period. The long-term earnings growth rate for AVT is currently projected at 37.2%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Agilent (A) to Provide Genomics Innovation Via New Tie-Ups
Agilent Technologies (A - Free Report) recently collaborated with Amazon’s (AMZN - Free Report) cloud computing platform Amazon Web Services (AWS) and NVIDIA (NVDA - Free Report) .
Per the terms of the deal, Agilent will leverage Amazon Elastic Compute Cloud G5g instances, NVIDIA T4G Tensor Core GPUs and NVIDIA Clara Parabricks’ advanced genomics analysis capabilities for improving processing speeds for variant calling workflows on its cloud-native Alissa Reporter software.
With the integration of NVIDIA Clara Parabricks platform into the Alissa secondary analysis pipelines, clinical labs and researchers can avail quick panel-specific data analysis solutions in a secure manner.
On the back of this partnership, Agilent aims to provide streamlined workflow solutions for its SureSelect family of next-generation sequencing (NGS) assays, which include a wide range of custom and catalog panels.
Notably, SureSelect panels are widely used to enrich samples for specific genes of interest as they ensure a cost-effective targeted sequencing process. With Amazon AWS’ cloud-based analysis expertise and NVIDIA’s compute capabilities, Agilent will advance this process and provide advanced analytical solutions in the genomics space.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote
Key Prospects
The recent tie-up with Amazon’s AWS and NVIDIA is anticipated to help Agilent expand its presence in the booming genomics market.
The underlined market is witnessing significant growth owing to rising demand for genome sequencing for the diagnosis of critical diseases like cancer. Growing adoption of new products and software for storage, sequencing and analysis of large DNA information is further driving this market.
Per a Fortune Business Insights report, the market is expected to reach $94.7 billion in 2028, witnessing a CAGR of 19.4% between 2021 and 2028.
Also, a Grand View Research report states that the market is likely to see a CAGR of 15.4% during the same period.
A Slew of Partnerships
Agilent is consistently building partnerships to provide advanced technological solutions to serve its customers better.
Apart from the recent alliance, Agilent collaborated with APC Ltd., a provider of innovative small molecule and large molecule process design and process development solutions. Per the terms of the agreement, A aims to help customers in the biopharmaceutical and pharmaceutical industry develop higher quality drugs faster.
Moreover, Agilent is working with the Advanced Mammalian Biomanufacturing Innovation Center to advance technologies and bring innovative measurement tools for bioprocess development, and biomolecular, cell and gene-based therapeutics manufacturing applications.
Agilent also joined forces with Virtual Control whereby it integrated the latter’s advanced artificial intelligence technology into its industry-leading gas chromatography and mass spectrometry platforms to enhance lab productivity.
Zacks Rank & Another Stock to Consider
Currently, Agilent carries a Zacks Rank #2 (Buy). Investors interested in the broader technology sector can also consider another top-ranked stock like Avnet (AVT - Free Report) , flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Avnet has gained 19% in the year-to-date period. The long-term earnings growth rate for AVT is currently projected at 37.2%.